Aura Biosciences updates corporate presentation for J.P. Morgan Healthcare Conference

Aura Biosciences, Inc.

Attending 41st Annual J.P. Morgan Healthcare Conference starting January 9, 2023 in San Francisco.
Updated corporate presentation filed as Exhibit 99.1 for investor meetings.
Forward-looking statements caution about risks including clinical trials and regulatory approvals.
Company's product candidate belzupacap sarotalocan for choroidal melanoma is highlighted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.